Key stats
Market capitalization
87.021MUSD
Dividends yield (FY)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
−2.37USD
ISIN
US50107A1043
Sector
Health Technology
Industry
Pharmaceuticals: Major
Website
kronosbio.com
Headquarters
San Mateo
Employees
97
Founded
2017
Kronos Bio, Inc. is a clinical development biopharmaceutical company. It engages in the business of developing therapeutics that target dysregulated transcription that causes cancer and other serious diseases. The company was founded by Arie S. Belldegrun, Joshua A. Kazam, David M. Tanen, and Christopher Wilfong on June 2, 2017 and is headquartered in San Mateo, CA.
Income Statement
Balance Sheet
Cash Flow
Earnings
Next:—
Revenue